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Abstract
Introduction: “Treat All” – the treatment of all people with HIV, irrespective of disease stage or CD4 cell count – represents
a paradigm shift in HIV care that has the potential to end AIDS as a public health threat. With accelerating implementation of
Treat All in sub-Saharan Africa (SSA), there is a need for a focused agenda and research to identify and inform strategies for
promoting timely uptake of HIV treatment, retention in care, and sustained viral suppression and addressing bottlenecks
impeding implementation.
Methods: The Delphi approach was used to develop consensus around research priorities for Treat All implementation in
SSA. Through an iterative process (June 2017 to March 2018), a set of research priorities was collectively formulated and
refined by a technical working group and shared for review, deliberation and prioritization by more than 200 researchers,
implementation experts, policy/decision-makers, and HIV community representatives in East, Central, Southern and West
Africa.
Results and discussion: The process resulted in a list of nine research priorities for generating evidence to guide Treat All
policies, implementation strategies and monitoring efforts. These priorities highlight the need for increased focus on adoles-
cents, men, and those with mental health and substance use disorders – groups that remain underserved in SSA and for whom
more effective testing, linkage and care strategies need to be identified. The priorities also reflect consensus on the need to:
(1) generate accurate national and sub-national estimates of the size of key populations and describe those who remain under-
served along the HIV-care continuum; (2) characterize the timeliness of HIV care and short- and long-term HIV care contin-
uum outcomes, as well as factors influencing timely achievement of these outcomes; (3) estimate the incidence and prevalence
of HIV-drug resistance and regimen switching; and (4) identify cost-effective and affordable service delivery models and strate-
gies to optimize uptake and minimize gaps, disparities, and losses along the HIV-care continuum, particularly among under-
served populations.
Conclusions: Reflecting consensus among a broad group of experts, researchers, policy- and decision-makers, PLWH, and
other stakeholders, the resulting research priorities highlight important evidence gaps that are relevant for ministries of health,
funders, normative bodies and research networks.
Keywords: Treat All; universal HIV treatment; 90-90-90 targets; sub-Saharan Africa; implementation science
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1 | INTRODUCTION
The World Health Organization’s (WHO) “Treat All” guidance
of September 2015, which recommended that all individuals
be treated as soon as possible after HIV infection and diagno-
sis [1], was a true paradigm shift in HIV care and treatment
[2]. Preventing illness and death among people living with HIV
and averting new infections by reducing onward HIV transmis-
sion, Treat All is recognized as the primary strategy for achiev-
ing the Joint United Nations Programme on HIV/AIDS
(UNAIDS) 90-90-90 targets [3–5] (Box 1). In view of its
potential contribution to ending AIDS as a public health
threat, Treat All is being adopted in countries around the
globe.
By 2017, most countries in sub-Saharan Africa (SSA) had
adopted some form of the Treat All recommendation (Fig-
ure 1) [2,6–8]. Nonetheless, new HIV infections and AIDS-
related mortality remain higher in SSA than other world
regions, and the majority of people living with undiagnosed
and untreated HIV infection live in SSA [9]. To address high
unmet need for HIV care and treatment and accelerate pro-
gress towards the UNAIDS 90-90-90 targets in SSA, policy-
makers and planners need evidence on effective strategies for
promoting uptake of services and maximizing their impact on
individual and population health outcomes, and on how best
to address major bottlenecks impeding effective and efficient
implementation of Treat All. To catalyze efforts to address
these important evidence gaps, a global group of expert clini-
cians, researchers and programme specialists engaged in HIV
research and service delivery in SSA undertook a multi-step
process to identify a set of initial research priorities with the
potential to inform and guide Treat All implementation. With
the rollout of Treat All accelerating in SSA in 2017, the aim of
this process was to ensure that evidence on the implementa-
tion and scale-up of Treat All policies is systematically gath-
ered and examined to identify optimal programmatic
strategies and to realize the individual and public health bene-
fits of earlier HIV treatment more rapidly [10–12].
2 | METHODS
The Delphi method was used to develop and refine Treat All
research priorities. The Delphi method is a flexible approach,
widely used to reach consensus among experts in health
research and other disciplines [13–18]. The Delphi method
generally involves an iterative process of eliciting and aggre-
gating opinions from a group of experts, with opportunities
for participants to provide input during each round and to
reassess and incorporate new insights and perspectives during
subsequent rounds. A key feature of the Delphi method is
that participants provide input independently during each
round, resulting in a process that is not unduly influenced by
any one individual or subset of participants [13,14].
The process for reaching consensus around Treat All
research priorities involved six phases, carried out between
June 2017 and March 2018 (Figure 2). This process was led
by a group of researchers involved in the International epi-
demiology Databases to Evaluate AIDS (IeDEA) consortium, a
global collaboration that consolidates, curates and analyses
longitudinal data on care and treatment of PLWH (Box 2).
2.1 | Round 1
A core group of 25 IeDEA investigators were invited to par-
ticipate in a Treat All Consensus Statement Working Group,
based on their expertise leading HIV research in 10 popula-
tion-specific and/or cross-cutting content areas (see Box 3).
Subsequently, 15 working group members reviewed and sum-
marized the literature [2] in their respective areas of expertise
and proposed an initial list of 83 research priorities across the
10 content areas.
2.2 | Round 2
Via an online Qualtrics [19] survey, members of the working
group were asked to anonymously rate (without ranking) the
overall importance of each of the 83 proposed research
Box 1. Key Terms and Definitions
Treat All: The Treat All approach recognizes that HIV infection should be treated as soon as possible after diagnosis because
all patients, regardless of their stage of infection, benefit clinically from early treatment of HIV. In addition, because reduction
in HIV viral load to undetectable levels eliminates the risk of onward transmission, the Treat All approach has the potential to
provide the population health benefit of reducing HIV incidence. Treat All therefore is inclusive of efforts to diagnose and
treat all persons with HIV as soon as possible after HIV infection.
UNAIDS 90-90-90 Targets: In 2014, the Joint United Nations Programme on HIV/AIDS and partners set targets to diagnose
90% of the people living with HIV (PLWH), provide treatment to 90% of those diagnosed with HIV, and achieve viral suppres-
sion among 90% of those on treatment by 2020 to help end the AIDS epidemic by 2030.
Key and Underserved Populations: We use the term Key Populations to refer to groups of people who are more likely to be
exposed to HIV or to transmit it, and whose engagement is critical to a successful HIV response [65]. Depending on the epi-
demic context and setting, key populations may include infants/children, adolescents, younger adults, men, women, older
adults, female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), transgender (TG)
individuals and migrant/mobile populations. “Underserved” refers to an unmet need for HIV care services, including both test-
ing and treatment services.
Yotebieng M et al. Journal of the International AIDS Society 2019, 22:e25218
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25218/full | https://doi.org/10.1002/jia2.25218
2
priorities, using a scale of 1 (least important) to 5 (most
important). Respondents were also asked to provide feedback
on whether each research priority was sufficiently specific and
clear, and to suggest additional research priorities in response
to perceived gaps. Sixteen out of 25 working group members
(64%) participated in the survey, and 32 out of 83 research
priorities were rated both “high” in importance (i.e. a “4” or “5”
rating) and clear/specific by at least two-thirds of respondents.
In addition, eight new research priorities were proposed,
resulting in a list of 40 research priorities.
2.3 | Round 3
The revised list of 40 research priorities (in English and
French) was distributed to the working group, as well as to a
broader group of 203 researchers and stakeholders who were
registered to attend a meeting on “Treat All” organized by the
IeDEA consortium in Kigali, Rwanda. This meeting involved
researchers and clinic staff involved in IeDEA in East, Central,
Southern and West Africa, along with representatives from
the Government of Rwanda, HIV policy and implementation
Figure 1. Uptake of national ‘Treat all’ policies for adults and adolescents with HIV, July 2017. (Source: WHO)
Round 1: Literature 
scans and initial list of 
research priorities 
formulated
(N = 83 priorities)
Round 2: Rating and 
selection of most 
important priorities and 
incorporation of new 
priorities (N = 40 priorities)
Round 3: Rating of 40 
research priorities
Round 4: Selection of 
most critical research 
priorities by 90-90-90 
goal (N = 16 priorities)
Round 5: Refinement 
and consolidation of 
research priorities 
(N = 9 priorities)
Round 6: Final rating of 
9 research priorities
Figure 2. Consensus development process.
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experts, donor representatives, other non-IeDEA affiliated
researchers, and representatives from four advocacy organiza-
tions representing the HIV community. Via a second Qualtrics
survey, all 203 meeting registrants, including members of the
working group, were invited to review and anonymously rate
the list of 40 research priorities, using the same five-point rat-
ing scale. Survey responses were received from 72/203 (36%)
researchers from 14 countries. Mean ratings and the propor-
tion of respondents rating each research priority a “5” (high-
est) in importance were calculated.
2.4 | Round 4
At the Kigali meeting in November 2017, all 203 attendees
(100%) actively participated in breakout sessions to further
refine the research priorities. Meeting attendees self-selected
into three groups, each focused on a different 90-90-90 tar-
get (i.e. diagnosis, treatment, or viral suppression). Each group
reviewed the list of 40 research priorities and their ratings
from Round 3 and deliberated to reach consensus on five to
seven priorities most critical for attaining the group’s respec-
tive 90-90-90 target. Groups were also encouraged to modify
the proposed priorities to reflect important topics that had
not been identified a priori. This process resulted in a com-
bined list of 16 research priorities.
2.5 | Round 5
In follow-up to the Kigali meeting, 21 members of the working
group participated in two teleconference calls to review the
research priorities recommended by the three breakout groups
and to discuss areas of overlap and ways to combine research pri-
orities. This step produced a final list of nine research priorities.
2.6 | Round 6
The last round of the Delphi process was designed to assess
the degree of consensus around the final list of research pri-
orities. In January 2018, individualized survey links for a third
and final online Qualtrics survey (in both English and French)
were sent to all Kigali meeting participants and working group
members. As with previous rounds, respondents were invited
to rate each research priority on a five-point scale in terms of
its importance to Treat All implementation. Responses were
received from 93/203 participants (46%), and mean ratings
and the proportion rating each priority a “4” or “5” in impor-
tance were calculated.
2.7 | Human subjects
The protocol for this project was reviewed by the Institutional
Review Board (IRB) at the City University of New York School
of Public Health.
3 | RESULTS
3.1 | Rating of and consensus on research priorities
More than 200 individuals participated in one or more rounds
of the research prioritization process, representing 12 coun-
tries in SSA (Burundi, Cameroon, Co^te d’Ivoire, Democratic
Republic of Congo, Kenya, Nigeria, Republic of the Congo,
Rwanda, Senegal, South Africa, Tanzania and Uganda), as well
Box 2. IeDEA
IeDEA is an international research consortium established in 2005 by the
U.S. National Institute of Allergy and Infectious Diseases (NIAID) to provide
a rich resource for globally diverse HIV/data (see www.iedea.org). The
IeDEA Cohort Consortium collaborates to collect and harmonize clinical
care data as a cost-effective means of generating large data sets to address
high priority research questions and streamline HIV/AIDS research.
The Consortium includes 140 clinics (denoted by ⊙) in sub-Saharan Africa
that have provided care to more than 1 million PLWH. Representing 23 SSA
countries, IeDEA is poised to provide some of the first data on the uptake and
outcomes of Treat All implementation.
Box 3. Population-specific and cross-cutting content
areas of expertise
Populations
• Infants and children
• Adolescents
• Adults
• Pregnant and postpartum women
• Key populations (sex workers, people who inject drugs,
men who have sex with men, mobile populations)
Cross-cutting content areas
• Metrics and monitoring
• Models of care/strategies
• Policy modelling
• Mental health
• Substance use
Locaon of IeDEA sites in SSA
Yellow: West Africa 
Green: Central Africa 
Orange: East Africa
Purple: Southern Africa
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as Europe (France and Switzerland) and North America (Uni-
ted States). While 123/203 (61%) of these individuals partici-
pated in at least one of the research priority rating surveys,
the final list of nine research priorities was rated by 93 partic-
ipants (response rate of 46%). Almost two-thirds (60%) of
those who participated in the final rating of research priorities
were based in SSA, 12% of respondents were based in Eur-
ope, and 28% were based in the United States. One-fifth of
respondents completed the survey in French. Respondents’
backgrounds and areas of work included clinical research and
implementation science (71%), service provision (25%), pro-
gramme management (16%), policy-making or advocacy (6%),
and other (10%), with about one-fourth reporting multiple
areas (e.g. research and service provision, programme manage-
ment and research). Respondents reported a mean of
10 years of experience working in HIV/AIDS, across various
disciplines, including adult HIV (54%), adolescents (35%),
infants and children (29%), key populations (27%), maternal
and child health/prevention of mother-to-child transmission
(26%), metrics and monitoring (18%), mental health disorders
(12%), models of care (10%), substance use disorders (8%)
and policy modelling (6%).
There was a high level of consensus across the final list of
9 research priorities, with 73.9% to 91.3% of respondents
providing ratings of a “4” or “5” in importance (Table 1). In
analyses stratified by respondent characteristics (e.g. identifi-
cation as a researcher vs. non-researcher, engagement in
local/national policy-making, residence in SSA, survey lan-
guage), there were few differences in ratings, with the excep-
tion of Research Priority 1 (Generate accurate national and sub-
national estimates of the number and proportion of persons living
with HIV who are undiagnosed, disaggregated by age, sex, and
population group) which was rated higher in importance by
members of the working group than other respondents (4.7
vs. 4.3, p < 0.05; 100% vs. 81% rating as a “4” or “5”).
3.2 | Research priorities
The final research priorities are presented in Table 1, with
illustrative research questions related to each priority
Table 1. Treat All research priorities
Generating metrics, estimates, and evidence to guide Treat All policies, planning, monitoring and
evaluation, and intervention development, with key metrics disaggregated by age, sex and population
group
Mean rating
% rating “4” or “5”
in importance for Treat All
1. Generate accurate national and sub-national estimates of the number and proportion of persons living with
HIV who are undiagnosed
Mean: 4.4
Rating “5”: 57.6%
Rating “4” or “5”: 85.9%
2. Characterize and understand critical facilitators of and barriers to timely diagnosis, care linkage,
antiretroviral therapy (ART) initiation, sustained care engagement, and ART adherence, particularly for key
populations and underserved groups, including infants, adolescents and men
Mean: 4.7
Rating “5”: 76.1%
Rating “4” or “5”: 91.3%
3. Develop and validate country-specific policy models to support decision-making around Treat All
implementation
Mean: 4.2
Rating “5”: 41.8%
Rating “4” or “5”: 78.0%
4. Develop and apply metrics that reflect the timeliness with which short-term and long-term HIV care
continuum outcomes are achieved
Mean: 4.1
Rating “5”: 44.1%
Rating “4” or “5”: 77.4%
5. Estimate the incidence and prevalence of HIV drug resistance, as well as switching from second to third-line
regimens at national and subnational levels
Mean: 4.2
Rating “5”: 45.2%
Rating “4” or “5”: 82.8%
Intervention effectiveness trials and economic evaluations to improve the rollout of Treat All and its effect on
the achievement of 90-90-90 goals
6. Identify service delivery models and strategies to optimize uptake of HIV testing, including repeat testing
and linkage to care for key and underserved populations
Mean: 4.3
Rating “5”: 50.0%
Rating “4” or “5”: 85.9%
7. Identify service delivery models and strategies to reduce the time from diagnosis to ART initiation for key
and underserved populations
Mean: 4.3
Rating “5”: 50.6%
Rating “4” or “5”: 82.4%
8. Identify service delivery models and strategies to improve early and sustained viral suppression, early
identification of drug resistance, and timely regimen switching
Mean: 4.5
Rating “5”: 62.0%
Rating “4” or “5”: 89.1%
9. Identify screening, diagnostic, and treatment interventions for mental health and substance use disorders
that can be integrated into HIV care to improve timely diagnosis, ART initiation, retention in care and viral
suppression
Mean: 4.1
Rating “5”: 39.1%
Rating “4” or “5”: 73.9%
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Table 2. Illustrative research questions and possible methods to address them
Research questions Methods
Research Priority 1: Generate accurate national and sub-national estimates of the number and proportion of persons living with HIV who
are undiagnosed
• What is the prevalence of undiagnosed HIV, particularly for key
and priority population groups (e.g. MSM, SW, PWID, infants, ado-
lescent, pregnant women, men), and what is the size of key popula-
tion groups (e.g. MSM, SW, PWID) at national and subnational
levels?
• How does the prevalence of undiagnosed HIV vary by sub-national
geographic area?
• Routine monitoring data; serosurveys, biobehavioural surveys;
modelling.
Research Priority 2: Characterize and understand critical facilitators of and barriers to timely diagnosis, care linkage, ART initiation, and sustained
care engagement and ART adherence, particularly for key populations and underserved groups, including infants, adolescents, and men
• What factors (individual, cultural, and structural/systems) influence
timely diagnosis of HIV (i.e. at higher CD4 counts) and timely link-
age to HIV care? How does this vary by sociodemographics and
for key and underserved populations (e.g. MSM, SW, PWID,
infants, adolescents, men)?
• Mixed methods approaches with PLWH, providers, and policy
makers; implementation science/intervention studies; studies
exploring new settings for HIV testing.
Research Priority 3: Develop and validate country-specific policy models to support decision-making around Treat All implementation
• What are the country-specific health and economic outcomes,
including cost-effectiveness and budget impact, associated with
Treat All implementation?
• How should interventions that address local implementation chal-
lenges (e.g. advanced HIV at entry to care; loss to follow-up;
acquired and developed viral resistance) be efficiently prioritized?
• What strategies can best engage local decision makers in mathe-
matical model development and translation of model findings into
policy?
• Mathematical modelling; cost-effectiveness and other economic
studies; stakeholder meetings; key informant interviews.
Research Priority 4: Develop and apply metrics that reflect the timeliness with which short-term and long-term HIV care continuum
outcomes are achieved (i.e. early diagnosis, rapid linkage to care following diagnosis, rapid ART initiation following linkage, viral suppression
within 4 weeks of ART initiation, and rapid achievement of sustained viral suppression)
• What is the most appropriate care cascade metric for Treat All
and what metrics should be used to monitor it? Is it possible to
develop a metric of time from infection to ART initiation?
• What is the optimal timing of ART initiation after diagnosis confir-
mation (e.g. immediately after diagnosis, after initial adherence
counselling, etc.) for maximizing retention in care, adherence, and
clinical outcomes, and how does this vary by population subgroup
and co-morbidities (e.g.patients with TB co-infection, substance
use and mental health disorders)?
• RCT or cluster RCT in real world implementation setting (vs.
research setting).
Research Priority 5: Estimate the incidence and prevalence of HIV drug resistance, as well as switch to second- and third-line regimens at
national and subnational levels
• What is the prevalence of acquired and developed HIV drug resis-
tance, and how does this vary across national, subnational and
patient populations?
• What is the rate of switching to second- and third-line regimens,
and how does this vary by setting and by patient characteristics
• Routine monitoring data; surveys; targeted studies at sentinel
HIV care sites.
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Table 2. (Continued)
Research questions Methods
Research Priority 6: Identify service delivery models and strategies to optimize uptake of HIV testing, including repeat testing and linkage to
care, for key and underserved populations
• What testing strategies and settings (e.g. self-testing, home-, and
community-testing, etc.) are effective in improving timely HIV diag-
nosis, for sociodemographic and other key subgroups (e.g. MSM,
SW, PWID), and underserved populations (infants, adolescents,
men, sexual partners of HIV-infected individuals)?
• Which testing strategies are most preferred by client subgroups?
Which can minimize stigma-related barriers to HIV testing?
• What clinic and community-based strategies are effective in
improving linkage to- and retention in care and sustained viral load
suppression?
• RCT/cluster RCT; hybrid trial design; mixed methods; discrete
choice experiments.
Research Priority 7: Identify service delivery models and strategies to reduce the time from diagnosis to ART initiation for key and
underserved populations
• What clinic and community-based strategies are effective in linking
patients to care, particularly for key and underserved populations
(e.g. MSM, SW, PWID; men and adolescents)?
• What clinic and community-based strategies are effective in ensur-
ing timely initiation of ART, particularly for key and underserved
populations?
• What strategies are effective in addressing stigma-related barriers
to HIV care?
• Which service models are most preferred by client subgroups and
care providers?
• Are strategies, such as integrated care, task-shifting, and commu-
nity- and home-based services an efficient use of scarce resources
under Treat All?
• Mixed methods; RCT/cluster RCT; hybrid trial design, cost-
effectiveness and other economic studies; discrete choice
experiments.
Research Priority 8: Identify service delivery models and strategies to improve early and sustained viral suppression, early identification of
drug resistance, and timely regimen switching
• What strategies are effective in ensuring early and sustained viral
suppression, particularly for key populations and priority sub-
groups (e.g. MSM, SW, PWID; men, adolescents and infants)?
• How can service integration strategies be used to support sus-
tained viral suppression, particularly for key populations and prior-
ity subgroups?
• What strategies are most effective in ensuring early identification
of drug resistance, and timely regimen switching?
• Mixed methods; RCT/cluster RCT; hybrid trial design; cost-
effectiveness and other economic studies.
Research Priority 9: Identify screening, diagnostic and treatment interventions for mental health and substance use disorders that can be
integrated into HIV care to improve timely diagnosis, ART initiation, retention and viral suppression
• What is the feasibility and acceptability of integrating screening,
diagnosis, and treatment (pharmacological and non-pharmacologi-
cal) of mental health and substance use disorders (MH/SUD) and
into HIV care delivered by lay healthcare workers?
• What are effective strategies of integrating mental health and sub-
stance use disorders screening, diagnosis, and treatment into HIV
care, particularly for improving timely diagnosis, ART initiation,
retention and viral suppression.
• How can effective models for screening, diagnosis, and treatment
of MH/SUD within HIV clinic settings be scaled-up?
• What are the health outcomes, economic costs, and cost-effective-
ness of integrating MH/SUD screening/diagnosis and treatment
within HIV clinic settings compared to current standard of care?
• Mixed methods; RCT/cluster RCT; hybrid trial design, cost-
effectiveness and other economic studies.
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presented in Table 2. Of the final list of nine research pri-
orities, five priorities are focused on generating critical met-
rics, estimates and evidence needed to inform policies,
planning, monitoring and evaluation related to Treat All
implementation. Four priorities relate to the need to con-
duct focused effectiveness trials and economic evaluations
to improve the rollout of Treat All. The research priorities
reflect consensus around the need to more fully character-
ize the barriers faced by key populations and underserved
groups along each step of the HIV care continuum and to
identify programmatic strategies and tailored models of care
that meet the preferences and needs of these populations.
Finally, the research priorities highlight the need for
enhanced metrics and data related to the timeliness of
achieving short- and long-term outcomes along the HIV care
continuum, with particular attention to drug resistance and
regimen switching.
3.2.1 | Research Priority 1: Generate accurate
national and sub-national estimates of the number and
proportion of persons living with HIV who are
undiagnosed
• Context: To achieve the “first 90” target, timely estimates of
the number and proportion of persons with undiagnosed
HIV infection are critical for countries to ensure that HIV
testing programmes are targeted appropriately and effi-
ciently [20,21]. One recent study that analysed population-
based Demographic and Health Survey (DHS) data from 16
SSA countries estimated that only 54% of people living with
HIV (range across countries 26% to 84%) were aware of
their status, contributing to delays in care enrollment and
ART initiation [22]. Men, adolescents, those with lower edu-
cation levels, and the poorest individuals are less likely to
be aware of their status, resulting in late initiation of treat-
ment, as well as lower and later attainment of viral suppres-
sion [22]. Infants less than 18 months of age are also at
risk of delays in care enrollment and treatment initiation
because of challenges in early infant diagnosis testing, espe-
cially in resource-limited settings [23,24]. Estimating the
“first 90” for key populations (e.g. men who have sex with
men [MSM], sex workers [SW], people who inject drugs
[PWID], etc.) is difficult in contexts with unknown popula-
tion size estimates [20,21].
• Research approaches: Population-based studies, such as
demographic and health surveys that evaluate the imple-
mentation of testing services, frequent (annual) targeted
HIV sero-prevalence surveys in sub-national geographic
areas, and biobehavioural surveys [20], may be necessary
for monitoring this population-level metric. Surveys should
report estimates disaggregated by sex and age, with finer
age disaggregations (e.g. two-year age ranges) used for chil-
dren and adolescents [25]. Studies leveraging health service
utilization data, including antenatal care and other sentinel
surveillance-based methods, can also provide information
about specific populations. Systematically characterizing
individuals diagnosed and enrolling in HIV care with
advanced disease can also provide insights about which
populations are not being reached with existing testing and
surveillance strategies.
3.2.2 | Research Priority 2: Characterize and
understand critical facilitators of and barriers to timely
diagnosis, care linkage, ART initiation, and sustained
care engagement and ART adherence, particularly for
key populations and underserved groups, including
infants, adolescents and men
• Context: Global data suggest that the timeliness of ART initi-
ation, as measured by the level of immunodeficiency at the
start of ART, is highly suboptimal in relation to WHO guide-
lines, particularly in SSA, where a recent analysis of data
from 767,000 patients in 21 countries showed that median
CD4 counts at ART initiation remained below 300 cells/
mm3 in 2015 [26]. Infants, adolescents, and men, in particu-
lar, are more likely to initiate treatment late and to not be
retained in care [24,25,27,28].
• Research approaches: Important factors for further study
include quality of care; policy and administrative require-
ments; costs of services, including user fees; HIV-related
stigma; integrated screening and treatment of other health
conditions (i.e. non-communicable diseases); and community-
and home-based services (e.g. home-based self-testing, pro-
vision of multi-month medication supplies, etc.). Mixed
methods approaches should be used to better understand
these barriers and their relative contribution to delays in
diagnosis, linkage, ART initiation, and viral suppression, as
well as to losses along the care continuum, particularly for
key populations. Additionally, mixed methods research, such
as discrete choice experiments [29,30], should be used to
identify preferences (i.e. facilitators) that could improve
timely uptake of testing, HIV care, and sustained care
engagement. The magnitude and type of HIV-related stigma,
and its impact must be measured along the care continuum.
3.2.3 | Research Priority 3: Develop and validate
country-specific policy models to support decision-
making around Treat All implementation
• Context: The use of mathematical modelling techniques, cou-
pled with detailed, individual-level observational data, can
inform Treat All policy questions, including the efficiency, pri-
oritization and affordability of HIV-related interventions [31].
A strong modelling literature confirms that earlier ART initia-
tion reduces morbidity and mortality, is cost-effective com-
pared to deferred ART initiation [32–39], and prevents new
HIV infections [32,40], which may reduce population-level
economic costs [31]. However, additional work is needed to
develop and validate mathematical models that better reflect
local clinical context (e.g. epidemiologic and clinical care data,
economic costs), integrate local health system constraints
(e.g. workforce capacity, antiretroviral stockouts, etc.), and
areas of potential health system improvement (e.g. integrated
care). Addressing these gaps will facilitate policy-relevant
modelling projections that inform cost-effectiveness of indi-
vidual interventions, the affordability of these interventions,
and allocative efficiency across interventions when resources
are constrained [31,41,42].
• Research approaches: The development of country-specific
mathematical models can provide projections of health and
economic outcomes related to Treat All, including budget
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impact, which is essential information for programme planning
and decision-making. A key component of this effort is incor-
porating realistic model assumptions and inputs that reflect
local treatment and care patterns. These include real-world
challenges and health system constraints surrounding late
diagnosis, linkage to care, ART initiation, de novo development
of viral resistance, sustained viral suppression, and reaching
key and underserved populations, all of which can inform con-
textually relevant analyses on the cost-effectiveness, afford-
ability and prioritization of alternative interventions to inform
local Treat All implementation. Evaluating approaches for
engaging decision-makers in mathematical modelling studies
can facilitate translation of study findings into policy and prac-
tice. Validation of modelling approaches and the use of obser-
vational data sources for deriving appropriate model
parameter estimates remain important research areas.
3.2.4 | Research Priority 4: Develop and apply metrics
that reflect the timeliness with which short-term and
long-term HIV care continuum outcomes are achieved
(i.e. early diagnosis, rapid linkage to care following
diagnosis, rapid ART initiation following linkage, viral
suppression within four weeks of ART initiation, and
rapid achievement of sustained viral suppression)
• Context: A priority for Treat All approaches is minimizing the
time between HIV infection and sustained viral suppression.
Shortening this period maximizes individual clinical benefit
and reduces the risk of onward transmission, ultimately
reducing both new infections and HIV-related morbidity and
mortality. Although the 90-90-90 targets and HIV care con-
tinua delineate important milestones, current metrics do not
reflect the timeliness with which these key outcomes are
achieved [43]. In addition, in some settings, routine HIV viral
load monitoring is infrequent, and pre-ART CD4 count moni-
toring is declining in frequency with Treat All implementa-
tion [44,45], which limits opportunities to evaluate individual
and public health impacts of HIV programming. Four key
metrics for assessing the timeliness of continuum milestones
include: (1) median CD4 count at diagnosis [46,47], care
enrollment [48,49], and ART initiation [26,45,50,51]; (2) time
between diagnosis, enrollment [52–54]; (3) time between
enrollment and ART initiation [49]; and (4) time to first HIV
viral suppression and sustained HIV viral suppression.
• Research approaches: Metrics for this research priority could
be generated from routinely collected, patient-level, program-
matic data. Where CD4 count and viral load data are not read-
ily available for a large enough proportion of clinics and
patients, it may be possible to produce estimates from a sys-
tematic sample of sites. Additionally, if such data are non-exis-
tent because of unavailability of testing or a lack of systematic
monitoring, sentinel sites could be established to do system-
atic CD4 count monitoring immediately prior to ART initiation
and viral load monitoring following ART initiation in accor-
dance with national protocols. Such metrics should be disag-
gregated by age, sex and population group (i.e. key and
underserved populations, as well as pregnant and breastfeed-
ing women) [55]. Implementers and researchers should also
consider disaggregating cascades by period of diagnosis or
enrollment, so that short-term outcomes of newly diagnosed
persons and new enrollees can be differentiated from patients
already enrolled in HIV care.
3.2.5 | Research Priority 5: Estimate the incidence
and prevalence of HIV drug resistance, as well as switch
to second- and third-line regimens at national and
subnational levels
• Context: Emerging HIV drug resistance, including transmit-
ted resistance to NNRTI-based first-line ART regimens, is a
growing clinical and public health concern [56,57]. As a
result, many countries are rolling out dolutegravir-based
ART as first-line therapy [58]. While implementation of
Treat All dictates that healthy patients with good immuno-
logical status and no clinical signs of disease initiate treat-
ment, these patients may have suboptimal treatment
adherence and lower rates of retention, raising risks for
development of drug resistance and subsequent transmis-
sion of resistant virus [59]. A recent review [57] and several
modelling studies have raised concerns about the potential
for an increasing rate of drug resistance associated with
Treat All strategies [56,60,61]. Routine viral load monitoring
and assessment of treatment adherence are therefore
essential for detecting virologic failure early and for limiting
the development of drug resistance [45]. Equally important
are data on the impact of patient “churn” (i.e. recurring
patient disengagement and re-engagement in care) on viral
suppression, disease progression, the emergence of viral
resistance, and the durability of ART – particularly for the
first-line regimens that form the backbone of care in SSA.
Such data are limited, particularly in settings where routine
pre-ART CD4 count monitoring has been discontinued
because it is not required for treatment initiation.
• Research approaches: Patient tracing studies should consider
including an array of evaluations, including care status, viral
load, CD4 count and genotyping, to estimate the true fre-
quency of these outcomes and to assess the effect of disen-
gagement from care on viral resistance. As loss to care and
patient churn vary by patient characteristics, disaggregating
results by sex, age and other key demographics (e.g. preg-
nancy status) will be important for understanding the dynam-
ics of treatment failure and drug resistance. In addition, the
impact of reduced treatment adherence or interruption of
ART on the development of drug resistance should be
assessed and compared among different treatment regimens.
Investigations should also explore early signs of non-adher-
ence (e.g. dose timing measures and drug level measure-
ments) among patients who are traced after being lost from
original clinic of enrolment. Models designed to capture
trends and drivers of drug resistance development are impor-
tant for predicting outcomes and assessing the effectiveness
of different treatment and monitoring strategies [57].
3.2.6 | Research Priority 6: Identify service delivery
models and strategies to optimize uptake of HIV testing,
including repeat testing and linkage to care, for key and
underserved populations
• Context: Stigma and discrimination remain important barri-
ers to HIV testing [62–64], and about half of all people
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living with HIV do not know their status [22]. Accordingly,
closing the testing gap via differentiated service models, tai-
lored approaches for populations at risk, and stigma reduc-
tion strategies is central to Treat All implementation [65].
For example, men are a particularly important group for tai-
lored testing strategies, as they are less likely to be tested
for HIV until they become ill [66–70]. A number of models
show promise for optimizing uptake of HIV testing and
screening, including home- and community-based testing,
index partner testing, the integration of HIV testing into
multi-disease community-level health campaigns, the use of
lay cadres to expand testing and linkage to care, and self-
testing [71–78].
• Research approaches: Cluster randomized controlled trials
(RCTs), rigorous programme evaluations, mixed methods
studies on optimal timing of and barriers to repeat testing,
and discrete choice experiments on preferences related to
testing location (home or community based) and modalities
(e.g. integration of HIV testing into other health services)
will aid in identifying effective strategies that improve early
diagnosis and linkage to care, particularly for underserved
groups.
3.2.7 | Research Priority 7: Identify service delivery
models and strategies to reduce the time from diagnosis
to ART initiation for key and underserved populations
• Context: With the rollout of Treat All, the public health
approaches that have been effective in the rapid scale-up of
treatment to date may not be sufficient for reaching the
90-90-90 targets and achieving epidemic control [79,80].
For the general population and key population groups (e.g.
MSM, SW, PWID, those with mental health or other sub-
stance use disorders, etc.), stigma remains a barrier to HIV
care, contributing to delays in ART initiation [63,81,82].
Men, particularly, are not adequately served by traditional
approaches, as they remain less likely than women to start
ART [27,83–86] and they have more advanced disease than
women when they start ART [27,87,88]. Wide-scale imple-
mentation of Option B+ may further increase gender dis-
parities in access to ART, as has been reported in Malawi
[89] and Mozambique [90]. Differentiated models of com-
munity- and facility-based care hold promise for reducing
the burden of clinic visits for both clients and providers,
while supporting ART initiation, adherence and retention in
care and improving health system cost efficiencies [79,91–
93].
• Research approaches: Rigorous programme monitoring
and evaluation, cohort studies, step-wedge trials, and
other implementation science approaches can be used
to generate evidence on the effects of differentiated
care models and integrated service delivery on patient
outcome measures across diverse epidemic contexts and
populations. Mixed methods studies would be useful to
identify specific populations who remain underserved by
conventional service delivery models and the role of
HIV-related stigma in limiting access for these groups.
Data are also needed on the cost and efficiency of vari-
ous models of HIV care delivery for priority and key
populations.
3.2.8 | Research Priority 8: Identify service delivery
models and strategies to improve early and sustained
viral suppression, early identification of drug resistance,
and timely regimen switching
• Context: Differentiated care strategies are essential for
meeting the needs of underserved groups and key popula-
tions who do not access routine services and/or require
additional support to achieve optimal HIV outcomes
[75,91,94–97]. It is estimated that about 15% of patients
on first-line ART do not achieve viral suppression within
12 months [98,99], with children and adolescents more
likely to have elevated viral loads [100–102]. Moreover,
even when patients fail to achieve viral suppression on first-
line ART, rates of regimen switching are lower than
expected, and loss to care rates are high [103,104]. Moni-
toring viral load and resistance is critical for ascertaining
patients’ status and the impact of treatment programmes.
• Research approaches: Additional research is needed on barri-
ers to viral suppression and regimen switching in response
to regimen failure/toxicity. Research is also needed to iden-
tify differentiated care models, enhanced adherence coun-
selling, enhanced patient monitoring or continuous quality
improvement techniques that can address the “failure cas-
cade” [103] and improve retention and viral suppression
rates, particularly for children, adolescents, and underserved
populations. Mathematical modelling studies can demon-
strate the importance and cost-effectiveness of routine viral
monitoring and resistance monitoring [57]. In addition, the
validation of algorithms for predicting treatment failure can
inform selective testing strategies for settings with limited
resources/capacity for routine viral load monitoring. Treat
All implementers and researchers can benefit from effec-
tiveness evaluations for current strategies to ensure timely
viral load monitoring and switching to second-line ART regi-
mens for those with detectable viral load. Qualitative
research to explore reasons why providers do not switch
patients to second-line regimens after first-line therapy fail-
ure are also important.
3.2.9 | Research Priority 9: Identify screening,
diagnostic, and treatment interventions for mental
health and substance use disorders that can be
integrated into HIV care to improve timely diagnosis,
ART initiation, retention and viral suppression
• Context: Mental health disorders (e.g. depression, post-trau-
matic stress disorder) are highly prevalent comorbidities in
PLWH, globally, with rates that exceed those in the general
population [105–107]. Substance use disorders (alcohol,
injection drugs and non-injection drugs) among PLWH are
also a growing concern in SSA [108–114]. While mental
health and substance use disorders are associated with sub-
optimal HIV treatment outcomes, including late ART initia-
tion, poor ART adherence, lack of viral suppression and
increased AIDS-related mortality [115–125], the coverage
of screening, diagnosis and treatment services for these dis-
orders is extremely limited in SSA [117,126,127]. Key con-
straints include workforce shortages, limited training on
mental health and substance use disorders, the lack of
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validated and culturally appropriate screening and diagnos-
tic tools, as well as the lack of proven treatment interven-
tions that can be integrated into HIV care and delivered by
non-specialists in contexts facing mental health and sub-
stance use workforce challenges [128–131].
• Research approaches: The magnitude of mental health and
substance use disorders merits further study, along with
the effects of integrated treatment for these disorders on
HIV outcomes under Treat All [105,108]. In addition, imple-
mentation science approaches should be used to assess the
delivery, efficiency, and effects of existing intervention mod-
els in SSA settings in order to identify scalable, cost-effec-
tive mental health and substance use interventions to
improve HIV outcomes. Such initiatives should prioritize
task-shifting modalities that can be integrated into HIV clin-
ics.
4 | DISCUSSION
With engagement and input from a diverse group of over 200
experts and stakeholders, our process yielded a set of
research priorities that an overwhelming majority of the group
agreed were important for the successful implementation of
Treat All policies in SSA. The priorities highlighted by this pro-
cess are broadly aligned with those identified by funding agen-
cies, such as the National Institutes of Health [132] and The
Global Fund [133], as well as the recent Lancet Commission
on strengthening the HIV response [134].
A persistent programmatic challenge reflected in these
research priorities is early diagnosis and linkage to care.
Recent data demonstrate that PLWH in the SSA region con-
tinue to initiate ART late [26], indicating that many PLWH live
for years before achieving first viral suppression. Late ART ini-
tiation has persisted [26,27] and is preventing more rapid
declines in HIV mortality and incidence in the region. Impor-
tantly, men, those experiencing multiple dimensions of stigma,
and other underserved populations are being left behind as
HIV treatment expands in SSA [63,66–70,81,135]. New age
and sex-disaggregated metrics and targeted strategies for ear-
lier diagnosis (i.e. at higher CD4 counts) and linkage to care
are needed. Although more real-world data on timely ART
uptake under Treat All implementation are needed, early evi-
dence on ‘Treat All’ in SSA and evidence from previous HIV
treatment guideline expansions suggest that if people are eligi-
ble for treatment when they link to care, they will start ART
rapidly with early retention in care and viral suppression fol-
lowing ART initiation [2,49].
Once treatment is initiated, there is a need for better met-
rics and monitoring related to sustained viral suppression,
treatment failure and regimen switching (i.e. second- and
third-line regimens). There is particular concern under Treat
All implementation that persons who are not experiencing any
clinical signs or symptoms may be at higher risk of disengage-
ment from care and poor treatment outcomes. Information on
these outcomes – disaggregated by age, sex and disease stage
– should be used to guide the development and deployment
of differentiated care strategies to maximize sustained viral
suppression and minimize the development of viral resistance.
Another major challenge is achieving optimal outcomes for
key and underserved populations and those with mental
health [105] and substance use disorders [108], making this a
critical area for investigation. Country-specific models and
modelling studies can help support these efforts by character-
izing the potential public health benefits to be gained through
optimal implementation of Treat All [31].
In pursuing these research priorities, it is critical to utilize
rigorous study designs (e.g. comparison groups whenever fea-
sible/possible) and to specify implementation approaches,
intervention components, and programme outcomes in order
to support the replication and adoption of effective strategies.
Ministries of health and donors can leverage programmatic
implementation opportunities that can support advancement
of the implementation science agenda around these priorities.
Through early and effective engagement of decision-makers,
researchers and implementers can ensure that their findings
are relevant and will be translated into policy, programmes
and services that ensure that the individual and population
health benefits of Treat All are realized sooner rather than
later.
5 | STRENGTHS AND LIMITATIONS
The use of a Delphi approach in formulating and refining a list
of research priorities to inform Treat All implementation lever-
aged the expertise of more than 200 researchers and part-
ners who work across no fewer than 23 SSA countries, as
well as the multi-disciplinary perspectives of an extended net-
work of implementation experts, researchers, policy-/decision-
makers, advocates and other stakeholders. The process also
facilitated the participation of researchers from both English-
and French-speaking contexts, with 20% of those participating
in the final round being French-speakers. Despite the diverse
backgrounds of participants, there was a high degree of con-
sensus in ratings of the research priorities across groups.
The Delphi approach provides a means of engaging diverse
participants in a research prioritization process, however, sus-
taining participation across rounds is a known challenge
[136,137]. In this initiative, participation varied considerably
across rounds, with more than 200 participants involved in
breakout sessions at the November 2017 meeting in Kigali to
identify five to seven priorities most critical for each of the
90-90-90 targets from a list of 40 proposed priorities. While
participation in online surveys in other rounds was lower, the
overall number of participants increased with each survey
round.
The Delphi method also allows for independent and decen-
tralized input from a diverse group of participants [14].
Nonetheless, the outcomes of the process are strongly shaped
by those who are most engaged. In this undertaking, the initial
working group was predominantly composed of IeDEA
researchers with backgrounds in clinical and epidemiological
research, rather than social science. For example, IeDEA
research primarily focuses on outcomes of patients already
diagnosed and enrolled in HIV care. While research related to
HIV testing strategies, community care, technological innova-
tion, and safer and more effective drugs are recognized as
vitally important, the backgrounds of participants in this process
resulted in a more emphasis on questions related to the second
and third 90-90-90 targets. Thus, there may be important
research priorities for some settings that are not reflected here.
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6 | CONCLUSIONS
While priorities for specific countries and contexts inevitably
will differ, the priorities generated through this modified Del-
phi process reflect the consensus of a broad group of individ-
uals actively engaged in addressing HIV throughout SSA. As
Treat All gains momentum in the region, these research priori-
ties highlight critical areas of inquiry with potential relevance
for ministries of health, funders, normative bodies, and other
research networks as they develop research agendas, pro-
gramme strategies, and funding priorities to accelerate pro-
gress in meeting the 90-90-90 goals.
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